KR102763369B1 - 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 - Google Patents

다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 Download PDF

Info

Publication number
KR102763369B1
KR102763369B1 KR1020207002328A KR20207002328A KR102763369B1 KR 102763369 B1 KR102763369 B1 KR 102763369B1 KR 1020207002328 A KR1020207002328 A KR 1020207002328A KR 20207002328 A KR20207002328 A KR 20207002328A KR 102763369 B1 KR102763369 B1 KR 102763369B1
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
ser
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207002328A
Other languages
English (en)
Korean (ko)
Other versions
KR20200092301A (ko
Inventor
이 주
올레 올슨
동 시아
데이비드 젤리맨
카트리나 비코바
앤-마리 루소
빌 브래디
블레어 렌쇼
브라이언 코바세비치
유 리앙
제렌 가오
Original Assignee
시스트이뮨, 인코포레이티드
바이리-바이오 (청두) 파마슈티칼 컴퍼니, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시스트이뮨, 인코포레이티드, 바이리-바이오 (청두) 파마슈티칼 컴퍼니, 리미티드 filed Critical 시스트이뮨, 인코포레이티드
Priority to KR1020257003259A priority Critical patent/KR20250024104A/ko
Publication of KR20200092301A publication Critical patent/KR20200092301A/ko
Application granted granted Critical
Publication of KR102763369B1 publication Critical patent/KR102763369B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207002328A 2017-06-25 2018-06-22 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 Active KR102763369B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257003259A KR20250024104A (ko) 2017-06-25 2018-06-22 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762524557P 2017-06-25 2017-06-25
US62/524,557 2017-06-25
PCT/US2018/039156 WO2019005639A2 (en) 2017-06-25 2018-06-22 MULTISPECIFIC ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257003259A Division KR20250024104A (ko) 2017-06-25 2018-06-22 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20200092301A KR20200092301A (ko) 2020-08-03
KR102763369B1 true KR102763369B1 (ko) 2025-02-05

Family

ID=64742644

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207002328A Active KR102763369B1 (ko) 2017-06-25 2018-06-22 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
KR1020257003259A Pending KR20250024104A (ko) 2017-06-25 2018-06-22 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257003259A Pending KR20250024104A (ko) 2017-06-25 2018-06-22 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도

Country Status (10)

Country Link
US (1) US11787863B2 (https=)
EP (1) EP3645049A4 (https=)
JP (1) JP7399852B2 (https=)
KR (2) KR102763369B1 (https=)
CN (4) CN110831973B (https=)
AU (2) AU2018295118B2 (https=)
CA (1) CA3068045A1 (https=)
IL (2) IL313468A (https=)
SG (1) SG11201912864SA (https=)
WO (1) WO2019005639A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI828625B (zh) * 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
US20200157224A1 (en) * 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
US20250376531A9 (en) * 2017-06-25 2025-12-11 Systimmune, Inc. Anti-4-1bb antibodies and methods of making and using thereof
EP3645738A4 (en) * 2017-06-25 2021-08-18 Systimmune, Inc. ANTI-PD-L1 ANTIBODIES AND METHOD FOR MANUFACTURING AND USING THEREOF
SG11202008474QA (en) * 2018-03-27 2020-10-29 Systimmune Inc Guidance and navigation control proteins and method of making and using thereof
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
JP7592712B2 (ja) * 2019-11-06 2024-12-02 システィミューン， インク． ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法
EP3988568A1 (en) * 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
US20250346681A1 (en) * 2022-04-11 2025-11-13 Astrazeneca Ab T cell binding proteins
AU2023409023A1 (en) * 2022-12-20 2025-07-31 Ho'ola Therapeutics Inc. Combination therapies for the treatment of cancer
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
CN116143934B (zh) * 2023-03-21 2023-07-25 诺赛联合(北京)生物医学科技有限公司 一种干细胞外泌体提取试剂盒及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004531263A (ja) * 2001-05-11 2004-10-14 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 特異的結合タンパク質およびその使用
JP2006512407A (ja) * 2002-09-27 2006-04-13 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体およびそれらの生成方法
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2611814A1 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
CN104072613A (zh) * 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
PE20120540A1 (es) * 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
US9580509B2 (en) * 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
ES2702315T3 (es) * 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
IL243311B (en) 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
EP3060579A1 (en) * 2013-10-25 2016-08-31 Numab AG Bispecific constructs and their use in the treatment of various diseases
EP3107569A4 (en) 2014-02-20 2018-02-21 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3253790A4 (en) * 2015-02-06 2018-07-25 University of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
CN104829733B (zh) * 2015-05-25 2018-06-05 广州百暨基因科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用
CA2998174A1 (en) * 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
TWI828625B (zh) * 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
US20200157224A1 (en) 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
SG11202008474QA (en) * 2018-03-27 2020-10-29 Systimmune Inc Guidance and navigation control proteins and method of making and using thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004531263A (ja) * 2001-05-11 2004-10-14 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 特異的結合タンパク質およびその使用
JP2006512407A (ja) * 2002-09-27 2006-04-13 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体およびそれらの生成方法
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies

Also Published As

Publication number Publication date
CN116199785A (zh) 2023-06-02
CN116041530A (zh) 2023-05-02
JP7399852B2 (ja) 2023-12-18
CN110831973A (zh) 2020-02-21
AU2025204860A1 (en) 2025-07-17
NZ760913A (en) 2024-10-25
WO2019005639A2 (en) 2019-01-03
JP2020530777A (ja) 2020-10-29
KR20250024104A (ko) 2025-02-18
IL271257B1 (en) 2024-07-01
IL313468A (en) 2024-08-01
EP3645049A4 (en) 2021-06-30
US20220002406A1 (en) 2022-01-06
KR20200092301A (ko) 2020-08-03
US11787863B2 (en) 2023-10-17
CN110831973B (zh) 2023-08-15
EP3645049A2 (en) 2020-05-06
CN116948035A (zh) 2023-10-27
AU2018295118B2 (en) 2025-04-17
IL271257A (en) 2020-01-30
AU2018295118A1 (en) 2020-02-06
IL271257B2 (en) 2024-11-01
WO2019005639A3 (en) 2019-02-07
CA3068045A1 (en) 2019-01-03
RU2020102662A (ru) 2021-07-27
SG11201912864SA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CN110891650B (zh) 制导和导航控制蛋白及其制造和使用方法
KR102763369B1 (ko) 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
KR102837521B1 (ko) Bcma에 결합하는 항체 및 이의 용도
KR102838340B1 (ko) 다중-특이적 항체 및 이들의 제조 및 사용 방법
AU2018250301B2 (en) Anti-ICOS agonist antibodies and uses thereof
CN106459203B (zh) 抗糖皮质激素诱导肿瘤坏死因子受体(gitr)的抗体及其用途
CN113939536B (zh) Tigit和pd-1/tigit-结合分子
JP7750887B2 (ja) 癌免疫療法のための併用療法での多重特異性抗体
RU2730674C2 (ru) Антитела, связывающиеся с человеческим каннабиноидным рецептором 1 (св1)
KR20220033522A (ko) 항-cd73 항체와의 조합 요법
CN110869390B (zh) 抗pd-l1抗体及其用途
KR20170091179A (ko) Fap 및 dr5에 특이적인 이중특이성 항체, dr5에 특이적인 항체 및 사용 방법
KR102558418B1 (ko) Pd-1에 결합하는 항체 및 그 용도
CN110869392A (zh) 用抗gitr激动性抗体治疗癌症
KR20220160555A (ko) Cd40에 결합하는 항체 및 이의 용도
AU2016330471A1 (en) Antibodies that bind human cannabinoid 1 (CB1) receptor
KR20160072268A (ko) 항-efna4 항체-약물 접합체
TW202313110A (zh) 癌症之治療
RU2837770C2 (ru) Мультиспецифические антитела и способы их получения и применения
RU2811477C2 (ru) Мультиспецифические антитела и способы их получения и применения
HK40018991B (zh) 多特异性抗体及其制备和使用方法
RU2773758C2 (ru) Связывающиеся с pd-1 антитела и способы их применения
RU2812280C1 (ru) Связывающиеся с pd-1 антитела и способы их применения
HK40019010B (zh) 多特异性抗体及其制备和使用方法
CN117460529A (zh) 抗icos抗体的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210622

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231023

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241029

PG1601 Publication of registration